1951 Northwestern Avenue
Stillwater,  MN  55082

United States
  • Booth: 4407


DiaSorin is an Italian multinational Group with over 40 years of experience in the in vitro diagnostic market. DiaSorin produces, develops and markets tests for the diagnosis of infectious diseases and hormonal disorders. DiaSorin tests are designed for hospitals and private testing laboratories within the immunodiagnostic and molecular diagnostic markets. We develop both high routine tests and specialty tests in a wide range of clinical areas, such as; Infectious Disease, Gastrointestinal Infections, Bone and Mineral, Endocrinology, and Hypertension. In the last 10 years DiaSorin focused its efforts to strengthen its position within the immunodiagnostic and molecular diagnostic segments. We are doing this by continuing to evolve our products in order to meet the needs of our customers by providing solutions that are: reliable, innovative, fully automated, and easy to use. Visit us at booth #4407 to learn more about our solutions we can offer your laboratory.

 Press Releases

  • February 21, 2017 - Saluggia (VC) - DiaSorin (FTSE Italia Mid Cap: DIA) announced today that they have received clearance from the US Food and Drug Administration to market the Simplexa C. difficile Direct Assay for the detection of Clostridium difficile (C. difficile).

    The assay, already launched outside of the US in November 2016, was developed by DiaSorin Molecular to be run on the LIAISON® MDX.  It is a scalable small bench-top instrument able to provide reliable, clinically validated, real-time PCR results for quantitative, qualitative, multi-analyte and sample-to-answer detection needs.

    Clostridium difficile Infection (CDI) is a major cause of antibiotic-associated diarrhea and colitis and is transmitted from person to person, by the fecal-oral route or acquired from environmental sources that have been contaminated.

    “C. difficile bacterial infections occur in all age groups and may be life-threatening, especially in elderly and immunocompromised patients,” said Michelle Tabb, Vice President of Research and Development, DiaSorin Molecular LLC. “Earlier intervention may lead to more effective infection control measures in a time where CDI is increasing the burden on healthcare systems with extended patient bed days, high readmission and mortality rates for susceptible patients.”

    According to the Centers for Disease Control and Prevention (CDC), approximately 15,000 deaths were attributed to CDI each year in the US and studies indicate that C. difficile has become the most common microbial cause of healthcare-associated infections in US hospitals costing up to $4.8 billion in excess health care costs.

     “The launch of C. Difficile molecular assay in US allow us to strengthen our positioning as a reliable infectious diseases company in a market where we see interesting growth opportunities,” commented Carlo Rosa, Chief Executive Officer of DiaSorin Group. “Our new assay is able to address the needs of hospital laboratories in regards to workflow and lab efficiency and have a positive impact on identifying C. difficile, leading to improve patient management.”

    About DiaSorin

    Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the diagnostic field to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostic market and a broad number of molecular diagnostic tests, which identify DiaSorin Group as the IVD “diagnostics specialist”.

    For additional information, please contact:

    Riccardo Fava                                                                                     Ines Di Terlizzi

    Investor Relations & Corporate Communication Senior Director         Investor Relator

    Tel: +39.0161.487988                                                                          Tel: +39.0161.487567   

    riccardo.fava@diasorin.it                                                                      ines.diterlizzi@diasorin.it


  • Simplexa® C. difficile Direct Assay
    DiaSorin recently launched the Simplexa® C. difficile Direct assay for detection of Clostridium difficile tcdB gene present in liquid or unformed stool samples without the need for nucleic acid extraction. The assay redefines workflow and performance with simple direct detection, less processing steps, excellent performance and low invalid rate....

  • Simplexa® C. difficile Direct Assay, recently launched from DiaSorin Molecular, is intended for use on the LIAISON MDX instrument for the detection of Clostridium difficile toxin B gene present in liquid or unformed stool samples.  The assay demonstrated excellent clinical agreement vs three on market assays, high NPV and low invalid rates. Additionally, it simplifies testing by utilizing direct detection without the need for nucleic acid extraction and allows for flexibility to run as little as 1 or up to 8 samples per run.  Visit the DiaSorin booth to learn how this assay redefines workflow combined with performance to meet laboratory needs.